Loading...
XLON
RUA
Market cap9mUSD
May 22, Last price  
11.50GBP
1D
-1.12%
1Q
-13.21%
Jan 2017
-42.19%
Name

Rua Life Sciences PLC

Chart & Performance

D1W1MN
P/E
—
P/S
325.74
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.06%
Rev. gr., 5y
36.46%
Revenues
2m
+0.55%
137,0001,425,000276,0001,484,0001,259,0001,362,0001,570,0003,146,7852,497,717251,379576,855625,564490,033404,000463,000489,0001,528,0001,625,0002,179,0002,191,000
Net income
-1m
L-28.11%
-1,867,000-523,000-2,121,000-1,159,000-1,249,000-1,923,000-2,501,00035,6020-493,758-219,433-419,357-189,149-34,000-609,000-816,000-1,451,000-2,067,000-2,003,000-1,440,000
CFO
-1m
L+13.12%
-2,119,000-1,288,000-816,000-1,139,000-1,389,000-2,050,000-1,527,00050,593346,192-23,998-189,81784,704-159,620347,000-429,000-431,000-1,423,000-2,361,000-1,174,000-1,328,000
Earnings
Jul 22, 2025

Profile

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
URL
https://rualifesciences.com/
IPO date
Feb 12, 1997
Employees
48
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
2,191
0.55%
2,179
34.09%
Cost of revenue
2,523
2,499
Unusual Expense (Income)
NOPBT
(332)
(320)
NOPBT Margin
Operating Taxes
(580)
(319)
Tax Rate
NOPAT
248
(1,000)
Net income
(1,440)
-28.11%
(2,003)
-3.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,974
BB yield
-131.55%
Debt
Debt current
117
110
Long-term debt
498
365
Deferred revenue
87
116
Other long-term liabilities
84
Net debt
(3,316)
(1,009)
Cash flow
Cash from operating activities
(1,328)
(1,174)
CAPEX
(55)
(449)
Cash from investing activities
(85)
(449)
Cash from financing activities
3,888
132
FCF
684
778
Balance
Cash
3,931
1,484
Long term investments
Excess cash
3,821
1,375
Stockholders' equity
(6,527)
(7,046)
Invested Capital
14,185
12,320
ROIC
1.87%
ROCE
EV
Common stock shares outstanding
33,566
22,185
Price
0.09
-82.52%
0.52
5.10%
Market cap
3,021
-73.56%
11,425
5.10%
EV
(295)
10,416
EBITDA
32
38
EV/EBITDA
274.11
Interest
83
16
Interest/NOPBT